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Abstract
Background: The vasoconstrictive protein TSP-1 is released from endothelial cells upon increased shear stress and
hypoxia. Both conditions are prevalent in pulmonary hypertension (PH). TSP-1 damages the local microcirculation
by disrupting pathways, which are essential for specific medical therapeutics. Furthermore, TSP-1 induces excessive
fibrosis and smooth muscle proliferation - a common finding in advanced PH - via TGF-ß and might promote
disease progression. The prognostic impact of circulating TSP-1, influence on hemodynamic parameters and
interaction with other biomarkers in patients with PH is incompletely understood.
This study examines prospectively circulating TSP-1 in association with hemodynamic parameters, clinical
variables and mortality.
Methods: Circulating TSP-1 was measured prospectively in 93 patients with precapillary PH undergoing right
heart catheterization and in 19 subjects without PH. TSP-1 levels were determined by ELISA and examined in
the context of hemodynamic variables. For evaluation of survival, patients were monitored for adverse events
on a 3-monthly basis and contacted at the end of the study after 5 years. In addition, levels of big-endothelin
and humoral cofactors of TSP-1 release were measured.
Results: Patients with PH had significantly increased TSP-1 levels compared to controls without PH (1114 ± 136 ng/mL
vs. 82.1 ± 15.8 ng/mL, p < 0.05). Levels were correlated with mean pulmonary artery pressure (PAPm, r = −0.58,
p < 0.001) and pulmonary vascular resistance (PVR, r = 0.33, p = 0.002). Survivors had lower TSP-levels as non-survivors
and all cause mortality associated with TSP-1 plasma levels above 2051 ng/mL (p = 0.0002, HR 1.49).
Conclusions: High plasma levels of TSP-1 are associated with increased PAPm, increased PVR and decreased survival.
Due to its interaction with therapeutic pathways, studies are warranted to clarify the impact of TSP-1 on of specific
medications for PH.
Background
Thrombospondin-1 (TSP-1) is a matricellular protein,
which is involved in various processes of inflammation,
neovascularization, hypoxia and remodeling [1–3]. A
major source of TSP-1 are the alpha-granules of platelets
[4]. Nevertheless, it is expressed in numerous cell types
like macrophages, endothelial cells, vascular smooth
muscle cells and cardiomyocytes [5–7]. Its production
increases dramatically under conditions of hypoxia,
altered shear stress or exposure to growth factors in-
cluding platelet derived growth factor and basic fibro-
blast growth factor [8]. These conditions are all present
in pulmonary hypertension. In vitro and in vivo studies
revealed three mechanisms of action of TSP-1. First,
binding to CD47 disrupts the nitric oxide pathway and
vascular endothelial growth factor pathways based on
the inhibition of soluble guanylyl cyclase and protein
kinase G in vascular smooth muscle cells [9]. Second,
in higher concentrations TSP-1 binds and activates
CD36, thereby decreasing intracellular cGMP-levels
due to interaction with cellular uptake of myristic acid
and decreased eNOS-dependent synthesis of nitric
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oxide [10]. The net result of TSP-1 binding to these
receptors is induction of apoptosis and abortion of
VEGF and nitric oxide signaling [11–13]. Finally,
TSP-1 is able to exert its biological effects by an
additional mechanism involving the activation of trans-
forming growth factor ß (TGF-ß) leading to excessive
fibrosis [14]. Therefore, TSP-1 is able to diminish the ef-
fects of specific therapeutics of PH and promote disease
progression of PH.
In this study we investigated the possible associations of
circulating TSP-1 with clinical as well as hemodynamic
variables and survival in PH. TSP-1 levels were compared
between a control group without PH, patients with
pulmonary arterial hypertension (PAH), lung disease
associated PH (LD) and chronic thromboembolic PH
(CTEPH). Furthermore, humoral cofactors of TSP-1
release were measured and analyzed.
Methods
Participants
Between June 2007 and December 2010, we enrolled
prospectively 19 control subjects and 93 patients pro-
spectively from the outpatient clinic for PH at the
Department of Pulmonology of the Saarland University
Hospital (Homburg / Saar, Germany). The control group
consisted of subjects without evidence of any internal
disease. In nine out of nineteen controls a right heart
catheterization was performed for exclusion of pulmon-
ary hypertension while in nine persons without any
medical history of chronic disease or respiratory symp-
toms, PH was considered absent. Cardiopulmonary func-
tion tests including echocardiography and right heart
cathererization were within normal range. The patients
had incident and prevalent diagnosis of PH and had
diagnostic workup according to current guidelines. Car-
diovascular diseases aside from PH were excluded prior
to inclusion into the study. Diagnosis of PH was based
on a mean pulmonary artery pressure above 25 mmHg
(PAPm) and a pulmonary artery occlusion pressure
(PAOP) below 15 mmHg. Cardiac output was determined
by thermodilution method. All patients received pulmon-
ary ventilation/perfusion scintigraphy to diagnose CTEPH.
Patients with suspected CTEPH had confirmatory pul-
monary angiography. The inclusion into the study was
irrespective of operability and plasma samples were taken
before planned pulmonary end-arterectomy. Both incident
as well as prevalent diagnosis of PH was included. Patients
were at least two months clinically and hemodynamically
stable before enrollment as indicated by unchanged func-
tional class, lack of hospitalization and stable medication.
The study complies with the declaration of Helsinki
and was approved by the local ethics committee
(Ethikkommission der Ärztekammer des Saarlandes,
Nr. 153/11). Written informed consent was obtained from
each patient.
Measurements
Blood was drawn during right heart catheterization as
initial work-up or follow-up. For platelet stabilization,
blood samples were collected into tubes containing
1 mL volume of citrate 109 mmol/l, theophylline 15
mmol/l, adenosine 3.7 mmol/l, dipyridamole 0.198
mmol/l. Plasma was separated by immediate centrifuga-
tion (2700xg at 4 °C, 20 min) and stored at −80 °C for
batch analysis. The local clinical laboratory determined
routine parameters.
TSP-1 levels were measured by ELISA in duplicates
according to the manufacturers instructions (Quantikine
human TSP-1 ELISA, R&D, Minneapolis, USA). Optical
density was determined using a Tecan Spectra III reader
set to 450 nm and 620 nm reference wavelength. The
TSP-1 assay had a minimal detection limit of 0.355 ng/mL.
The within run repeatability coefficient of variation was
5.1 %. Inter-assay repeatability was calculated with 11.3 %
resulting in an overall variability of 8.2 %.
PGDF-β platelet poor plasma levels were measured by
the Quantikine Human PDGF-β Immunoassay (R&D
Systems, Minneapolis, USA, Catalog Number DBB00).
Big-Endothelin ELISA was obtained from the Biomedica
Group (Vienna, Austria, Catalog Number BI-20082),
SDF1a and PF-4 ELISA from Ray Biotech, Inc. (Catalog
Number ELH-SDF1alpha-001, ELH-PF4-001). Measure-
ments were performed as indicated by the manufacturer.
Statistics
Continuous variables were tested for normality and vari-
ance homogeneity by Shapiro-Wilk test and Hartley´s
Fmax test respectively. Non-normally distributed variables
are expressed as median (range), normally distributed vari-
ables as mean ± SD unless indicated otherwise. Categorical
variables are expressed as numbers (percentage). Outliers
were defined outside a three-SD interval from mean of the
whole dataset. Differences between groups were tested by
ANOVA with post-hoc analysis (Dunnett T3 correction)
for normally distributed and Mann–Whitney-U-test for
non-normally distributed variables. Comparison of cat-
egorical variables was performed by Chi-square-test.
Regression analysis was studied for associations of
continuous variables. For bivariate regression a non-
parametric model was chosen with locally linear curve
fitting of the dataset.
Kaplan-Meyer-Analysis for death was performed with
an optimized cut-off of TSP-1 by minimized Matthews
coefficient. Hazard ratios were calculated using a cox
proportional hazard model (efron method). A p-value of
less than 0.05 (two-tailed) was considered statistically
significant in all tests.
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Data storage and processing, calculations, as well as




The characteristics of the study population are detailed
in Table 1 (n = 112). 93 patients and 19 control subjects
were enrolled. The mean age was slightly higher in
patients compared to control subjects (59 years vs.
47 years). 61 % of the population was female. Standard-
ized WHO functional class was provided by the treating
physician in our center. In the control group, workup
including laboratory examinations, cardiopulmonary
exercise test (CPET), catheter techniques (n = 9) and
pulmonary function testing, excluded physical illnesses
beyond reasonable doubt. The PAH group consisted of 35
patients with idiopathic PAH, 15 patients with associated
PAH (nine connective tissue disease, three Eisenmenger,
two sclerodermia, one HIV) and two patients with familial
PAH. Three patients had drug induced PAH. Patients with
LD had idiopathic pulmonary fibrosis (n = 11), COPD
(n = 6), one patient with exogenic allergic alveolitis, and
four patients with obstructive sleep apnea and fixed PH
under guideline therapy. 16 patients had chronic throm-
boembolic pulmonary hypertension, 38 patients (33.9 %)
were incident PH and treatment naïve upon inclusion.
Six minute walking distance (6MWD) was determined
according to guidelines. 79 % of patients were in func-
tional class II or III. Six minute walking distance in
control patients was 441 ± 68.4 m and significantly lower
in patients with PH patients (328 ± 142 m; p < 0.05).
Lowest values for 6MWD were observed in patients with
lung disease (243 ± 155 m), while patients with PAH had
a walking distance of 353 ± 111.3 m.
Current medication is summarized in Table 1. 20.4 % of
patients received no specific therapy at enrollment and
none of the control group received specific drugs. 75.3 %
of patients received one or two specific drugs, mostly
endothelin receptor antagonists (ERA) or phosphodieste-
rase inhibitors (PDEI). Only 4.3 % were on triple therapy.
Circulating TSP-1 and biomarker levels
Patients with PH had significantly higher levels of circula-
ting TSP-1 compared to healthy controls (Table 2, Fig. 1).
The subgroup analysis showed the lowest values within
the lung disease associated PH group (LD). Patients with
PAH or CTEPH demonstrated a 12.5 times and 22.6 times
increased concentration of circulating TSP-1 compared to
controls, respectively. Among all tested subjects, TSP-1 in-
creased with WHO functional class (Fig. 2, p < 0.001).
Comparing incident with prevalent PH, no significant dif-
ference in TSP-1 levels were found (752 vs. 1053 ng/mL,
p = 0.2) and no differences between hemodynamic param-
eters were apparent. No influence of either gender, age or
kidney function was statistically significant.
Patients with PDEI had lower TSP-1 levels compared to
patients without PDEI (1234 vs. 516 ng/mL, p = 0.02). In
contrast, ERA therapy had no effect on TSP-1 levels (806
vs. 1188 ng/ml, p = 0.1), while patients on PC-therapy had
higher TSP-1 levels (823 vs. 1762 ng/ml, p = 0.01).
Table 1 Basic characteristics of control group and patients grouped by DanaPoint classification
Control All PH PAH LD CTEPH
n 19 93 (100) 55 (59.1) 22 (23.7) 16 (17.2)
Male 7 37 19 15 3
Age [y] 47.2 ± 14.9 59.3 ± 15.8* 55.1 ± 16.9(*) 66.9 ± 13.0*,** 63.0 ± 9.9*,(**)
Height [cm] 169.2 ± 10.1 167.1 ± 9.8 165.6 ± 8.9 170.1 ± 11.9 168.4 ± 9.0
Weight [kg] 71.7 ± 17.3 81.0 ± 20.0(*) 81.6 ± 20.2 82.2 ± 23.7 76.8 ± 11.9
BSA [sqm] 1.81 ± 0.23 1.89 ± 0.24 1.88 ± 0.23 1.92 ± 0.30 1.87 ± 0.17
FC II-III 0 74 44 17 13
6MWD 441 ± 68.4 328 ± 142* 353 ± 110 243 ± 155*,** 347 ± 192(***)
PDEI 0 43 (46.2) 28 (51.0) 11 (50.0) 4 (25.0)
ERA 0 39 (41.9) 29 (52.7) 2 (9.1) 8 (50.0)
PC 0 14 (15.1) 12 (21.8) 0 12 (12.5)
Other 0 6 (9.5) 4 (10.8) 2 (11.8) 0
No drug 16 (83.4) 19 (20.4) 6 (10.9) 8 (36.4) 5 (31.3)
1 Drug 3 (16.6) 45 (48.4) 26 (47.3) 12 (54.5) 7 (43.7)
2 Drugs 0 25 (26.9) 19 (34.5) 2 (9.1) 4 (25.0)
≥3 Drugs 0 4 (4.3) 4 (7.3) 0 0
BSA body surface area determined by DuBois formula, FC modified NYHA functional class, 6MWD 6 min walking distance. Specific drug therapy: CCB calcium
channel blocker, PDEI phospho-diesterase inhibitor, ERA endothelin receptor antagonist, PC prostacyclin (inhaled/subcutaneous)
*p < 0.05 vs. Control, **p < 0.05 vs. PAH, ***p < 0.05 vs. LD, marks in brackets signify statistical trends (0.05 < p < 0.01), absolute case numbers (% of cases in group)
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Circulating levels of PDGF-β - a potent inductor of
TSP-1 - were elevated in PH compared to controls, with
PAH showing the highest levels followed by lung disease
associated PH. Levels of patients with CTEPH and PAH
were elevated but not statistically significant (Table 2).
Platelet factor 4 (PF4) is an established marker of
platelet activation and was determined in the same
plasma samples. Despite a trend to increased levels in
the PH group, none of the subgroups reached statistical
significance (Table 2). No correlation of PF4 and TSP-1
was detected (rho = 0.252 with p = 0.471).
Among many biomarkers SDF-1α has been promoted
to quantify endothelial shear stress. In patients with PH,
SDF-1α was increased significantly, but the subgroup
analysis produced no statistical significance for one of
the types of PH (Table 2).
Big-endothelin showed significantly increased levels in
both PAH and CTEPH patients, while levels in the group
with LD did not reach statistical significance. Highest
levels of big-endothelin were observed in CTEPH patients.
NT-pro-BNP was statistically significantly elevated in
PAH and CTEPH. The increased levels of NT-proBNP in
Table 2 Circulating biomarkers grouped according to DanaPoint classification
Control All PH PAH LD CTEPH
TSP-1 [ng/mL] 82.1 ± 15.8 1114* ±136 1025* ±161 799* ± 237 1852*,**,*** ±428
bigET [pg/mL] 1.22 ± 0.34 2.96* ±0.34 3.05* ±0.48 2.29 ± 0.53 4.06* ±0.75
PDGF-ββ [pg/mL] 152 ± 11 784* ±161 905 ± 253 652* ±145 382 ± 173
PF4 [pg/mL] 2.12 ± 0.25 3.05(*) ±0.29 2.81 ± 0.30 3.60 ± 0.72 2.95 ± 0.86
SDF-1α [pg/mL] 71.6 ± 8.7 124.5* ±14.2 128 ± 21.4 121 ± 17.1 116 ± 46.1
NT-proBNP [pg/mL] 128.0 ± 49 1212* ±214 1070* ±213 1529 ± 662 1296* ±495
Creatinine [mg/dL] 0.77 ± 0.22 1.01 ± 0.32* 1.06 ± 0.32* 0.95 ± 0.26 0.94 ± 0.35
Uric acid [mg/dL] 5.09 ± 1.41 7.56 ± 2.46* 7.20 ± 2.13* 7.70 ± 2.12* 8.93 ± 4.01*
Hb [g/dL] 14.2 ± 1.3 14.2 ± 2.4 14.6 ± 2.5 13.9 ± 2.3 13.5 ± 1.9
LDH [U/L] 199.9 ± 66.0 285.6 ± 91.0* 277.6 ± 62.0* 279.5 ± 70.9* 324.2 ± 173.2*
Bilirubin [mg/dL] 0.55 ± 0.20 0.80 ± 0.50 0.78 ± 0.47 0.78 ± 0.39 0.88 ± 0.75
TSP-1 thrombospondin 1, bigET big Endothelin, PDGF-ββ platelet derived growth factor ββ, PF4 platelet factor 4, SDF-1α stroma derived factor 1α, NT-proBNP
N-terminal pro-brain natriuretic peptide
Data is expressed as mean ± SD, *p < 0.05 vs. Control, **p < 0.05 vs. PAH, ***p < 0.05 vs. LD, marks in brackets signify statistical trends (0.05 < p < 0.01)
Fig. 1 Data represents mean ± SEM of circulating TSP-1 levels by groups according to Nice classification
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the lung disease group were not statistically significant
due to the high standard deviations (Table 2).
TSP-1 and hemodynamic parameters
The hemodynamic parameters are summarized in Table 3
as well as Additional file 1: Figure S1 and Additional file
2: Figure S2. Mean pulmonary artery pressure (PAPm)
correlated positively with TSP-1 (rho = 0.579, p < 0.001),
while cardiac output (CO) was negatively correlated
(rho = −0.338, p = 0.002). Therefore, an increased TSP-1
was found in hemodynamically compromised patients.
Consequently, PVR correlated positively with TSP-1
(rho = 0.331, p = 0.002). To demonstrate the complex
interrelation of hemodynamic parameters with circulat-
ing TSP-1, a locally linear non-parametric regression
was performed on TSP-1, PVR and cardiac index (Fig. 3).
Here, an increase of TSP-1 can be seen as pulmonary re-
sistance increases. In low resistance state, no TSP-1 is
produced over a large range of cardiac output. In
contrast, high resistance states produce a relative mini-
mum at normal cardiac output.
TSP-1 and outcome
To determine the impact of circulating TSP-1 on prog-
nosis, patients were followed by personal contact for five
years, there was no loss to follow up. At the end of the
study, 31 patients had died. Comparing survivors with
non-survivors after five years, non-survivors had more
than two-fold increased levels of circulating TSP-1
(Fig. 4). This was irrespective of the class of PH. Patients
with CTEPH had an overall increased level of TSP-1
though.
Using an optimized cut-off (minimal Matthew´s coeffi-
cient) of 2051 ng/mL, patients were grouped into high
levels and low levels of circulating TSP-1. The Kaplan-
Meier-analysis for survival showed a hazard ratio of 1.49
for cardiovascular death in case of TSP-1 levels above
2051 ng/mL (logrank test p = 0.002, Fig. 5).
Fig. 2 Data represents mean ± SEM of circulating TSP-1 levels by WHO functional class
Table 3 Summary of hemodynamic variables. All pressures are expressed in millimeter mercury
Control All PH PAH LD CTEPH
PAPm 15.4 ± 2.1 54.2 ± 19.0* 57.0 ± 18.4* 44.9 ± 16.5*,** 59.1 ± 21.8*,***
PAPsys 23.6 ± 4.3 76.8 ± 23.4* 79.3 ± 22.0* 67.2 ± 24.2*,(**) 82.7 ± 25.0*,(***)
PAPdia 10.7 ± 2.5 31.3 ± 11.7* 34.3 ± 12.6* 26.6 ± 8.5*,** 26.6 ± 7.9*,**
PAOP 7.8 ± 2.3 9.8 ± 2.5* 9.7 ± 2.5 10.1 ± 2.7 9.8 ± 2.0
TPG 7.7 ± 2.1 44.5 ± 19.6* 47.5 ± 19.0* 34.8 ± 17.1*,** 49.2 ± 22.2*,***
CI 2.67 ± 0.6 2.46 ± 0.7 2.36 ± 0.7 2.67 ± 0.4 2.52 ± 1.0
PVRI 250 ± 125 1282 ± 690* 1411 ± 730* 923 ± 472*,** 1326 ± 661*
PAPm mean pulmonary artery pressure, PAPsys systolic pulmonary artery pressure, PAPdia diastolic pulmonary artery pressure, PAOP pulmonary artery occlusion
pressure, TPG transpulmonary gradient, CI cardiac index [mL/min/sqm], PVRI, pulmonary vascular resistance index [dyn.s.cm−5.sqm]
Data is expressed as mean ± SD, *p < 0.05 vs. Control, **p < 0.05 vs. PAH, ***p < 0.05 vs. LD, marks in brackets signify statistical trends (0.05 < p < 0.01)
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Fig. 3 Locally linear non-parametric regression of circulating TSP-1 by PVRI and CI. The graph shows circulating TSP-1 levels based on a non-parametric
regression model, which uses linear functions to fit the local data points. The model resembles a saddle form, suggesting a relative minimum of net
TSP-1 production at normal CI and and increase of TSP-1 with both low and high CI. While TSP-1 increases with vascular resistance, extreme resistance
might be due to loss of total vascular area and therefore reduction of TSP-1 producing cells. Hence, TSP-1 levels follow a reverse U-shape. This
underlines the possible association of TSP-1 with shear stress at the pulmonary endothelium
Fig. 4 Data represents mean ± SEM of circulating TSP-1 levels by survivors and non-survivors in the various subtypes of PH
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Discussion
The presented study showed, that levels of circulating
TSP-1 differ significantly between patients with PH
compared to subjects without PH. The subgroup analysis
demonstrated the importance of the specific subtype of
PH for the interpretation of this biomarker. Further-
more, associations of circulating TSP-1-levels and pul-
monary hemodynamics were elaborated. And finally, the
association of elevated TSP-1 with increased mortality
became evident.
As Bauer and Isenberg showed, TSP-1 is abundantly
expressed in lung tissue of patients with PH. In pulmonary
endothelium, CD47 controls endothelial NO-synthase.
Binding of TSP-1 uncouples eNOS via CD47 and pro-
motes progress of hypoxic PH in animal models [15].
Furthermore, TSP-1 has been shown to deteriorate
shear stress dependent vasodilation under hypoxic con-
ditions and is induced by hypoxia in pulmonary vascu-
lar endothelium [16].
In this study we demonstrated a significant increase in
plasma levels of TSP-1 in patients with various types of
PH. While levels of TSP-1 varied in different subtypes of
PH, the common denominator was their hemodynamic
state. The univariate non-linear regression analysis showed
a significant association of circulating TSP-1 with PVR
and CO. This supports the initial hypothesis, that the in-
crease of PVR increases shear stress resulting in a release
of TSP-1 from pulmonary endothelial cells. However,
hemodynamic parameters to determine shear stress in
humans remain scarce. The extent of shear stress in a
specific pulmonary vessel is influenced by both right
ventricular function and properties of the vascular bed
of the lung. PVR and cardiac output remain the best
surrogate variables of standard right heart catheterization
for estimation of shear stress.
On the other hand it has been shown, that TSP-1
production is minimal at optimal shear rates [17],
explaining nonlinear U-shaped relation of shear stress
and TSP-1 release. In this study we showed first clinical
evidence for this complex relationship (Fig. 3), but had
to omit possibly confounding factors (i.e. age, medica-
tion) due to limited data points.
Induction of TSP-1 in endothelial cells has been
shown previously [18] and was confirmed for PAH [16].
Our data contrasts these findings, as an association of
TSP-1 with mixed central venous oxygen saturation,
which reflects peripheral oxygen depletion, could not be
confirmed. Furthermore, the vascular endothelium might
not be the only source of TSP-1 in PH, as increasing right
ventricular load might release TSP-1 from cardiomyocytes
as hemodynamics deteriorate. The release of TSP-1 from
the myocardium especially due to ischemia-reperfusion
injury has been shown previously [19] and might limit
specificity of TSP-1 as a marker for diagnosis of PH.
Fig. 5 Kaplan-Meier-Analyses of survival for death at an optimized cut-off of >2051 ng/mL TSP-1 in plasma, p = 0.03
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Experimental data supported the hypothesis of TSP-1
interfering with the NO-pathway [20]. This abrogates
soluble guanylate cyclase and protein kinase G as well
as adenylate cyclase [21–23], resulting in direct pul-
monary arterial vasoconstriction, disease progression
[16] and disruption of key pharmacological targets of
specific therapy.
Examination of drug regimes suggested lower TSP-1
levels on treatment with PDEIs, higher levels on PC-
treatment and intermediate levels under ERA treatment.
This observation might lead to the assumption, that
treatment regime was influential on circulating TSP-1.
On the other hand, PC therapy is an invasive therapeutic
concept and often withheld until treatment goals are not
sufficiently achieved by oral medications. Therefore,
these observations might reflect the finding, that TSP-1
was elevated with deteriorating hemodynamics and in-
creased functional class. The influence of medical ther-
apy on TSP-1 levels could not be determined in this
study and warrants longitudinal trials observing TSP-1
levels before and after initiation of new drug regimes.
As this study was designed as a cross-sectional observa-
tion, we included patients in different stages of disease.
While some had newly diagnosed PH, others were in the
final stage of their illness. Thus a non-matched compari-
son of TSP-1 levels between groups seems a serious limi-
tation for this study. The comparison of incident and
prevalent PH demonstrated slightly higher levels of TSP-1
in incident PH, statistical significance was not reached.
While the groups had similar hemodynamics, the influ-
ence of medication, the course of disease and adaptive
processes might lead to this finding. The reasons and
possibly influence on the prognostic value of TSP-1 was
beyond the scope of this cross-sectional pilot study.
Based on the data linking TSP-1 to hemodynamics
and the possibility of its negative impact on pathophysio-
logical mechanisms of PH, we sought to gain insight of
the prognosis attached to TSP-1 as a biomarker. At the
end of the study, survivor and non-survivors were com-
pared and in all groups non-survivors had significantly
higher levels of TSP-1 when entering the study (Fig. 4).
CTEPH patients demonstrated relatively higher levels in
both survivors and non-survivors compared to the other
subgroups. It is therefore mandatory to exactly classify the
type of PH before using TSP-1 as a potential biomarker.
Survival analysis in this study was based on follow-up
in regular intervals up to five years. The patients had re-
ceived standard therapy according to current guidelines.
Cardiovascular mortality was chosen as the primary end-
point, but in this dataset it was identical with all cause
mortality. We were able to show a significantly increased
mortality in patients with high TSP-1 levels. This data is
limited by the sample size of 93 patients and inclusion
of further confounding factors or multivariate analysis
with established predictors of mortality is obsolete.
Nevertheless, the optimized cut-off at 2051 ng/mL yielded
a highly significant difference between groups. Though, as
discussed above, the circulating levels of TSP-1 might vary
between subgroups and therefore a different cut-off can
be expected especially in patients with CTEPH. Fur-
thermore, serial measurements are needed to evaluate
the true impact on survival and various clinical events
in more complex frailty models.
Nevertheless, this data provides valuable information on
the relation of TSP-1 with pulmonary hemodynamics, a
clinical application of in vitro observations considering
crucial pathways in PH and indicates an impact on the
prognosis of a serious disease. These observations are
the clinical implication of previous studies on the role
of TSP-1 in experimental PH [15, 24].
The presented data might form the basis for evaluation
of TSP-1 as an indicator for the choice of medication
and might facilitate therapeutic decisions. TSP-1 interacts
significantly with the NO pathway, thereby leading to un-
coupling of specific therapeutic drugs [22]. Observational
studies should evaluate TSP-1 as a marker for possible
non-responders before initiation of therapy.
Conclusions
In this observational study, we could show that TSP-1
levels are significantly elevated in PH. While the majority
of studies focuses on strict selection of PH subgroups, this
cross-sectional pilot study was able to compare various
groups of precapillary PH. The association of TSP-1 levels
with invasive hemodynamic parameters offers insight into
the complex mechanisms of this disease. While current
biomarkers focus on the consequences of PH such as
myocardial damage, TSP-1 might monitor endothelial
injury and activation at the very source of the pathology.
In a prospective approach we were able to provide
five-year survival data from patients with PH. Despite
of the limited sample size, patients with elevated circu-
lating TSP-1 levels demonstrated a lower survival rate.
Therefore, prospective longitudinal studies are war-
ranted to provide insight in the usability of TSP-1 to
predict disease activity and progression and to confirm
the usefulness of this marker in various clinical end-
points and decisions.
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Additional file 1: Figure S1. Pulmonary artery pressures were
determined invasively. Data is expressed as mean ± SD [mmHg].
Statistically significance is denoted in Table 2 for readability. (TIFF 384 kb)
Additional file 2: Figure S2. Pulmonary vascular resistance index was
derived from invasive measurements of PAOP, mean PAP and cardiac output
by thermodilution method. Data is expressed as mean ± SD [dyn.s.cm−5].
Statistically significance is denoted in Table 2 for readability. (TIFF 270 kb)
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